VVC VVC Exploration Corporation

MethylGene Inc. (TSX:MYG) today reported topline results from its human efficacy
trial (Trial 290-005) with MGCD290, a novel antifungal agent targeting the
fungal enzyme, Hos2. Trial 290-005 was a randomized, multicenter, double-blind,
placebo-controlled trial designed to test whether MGCD290, in combination with
fluconazole, was superior to fluconazole alone in patients with
moderate-to-severe vulvovaginal candidiasis ("VVC"). 


The study showed no statistically significant benefit of MGCD290 plus
fluconazole compared to fluconazole alone. There were no serious
treatment-related adverse events and non-serious adverse events were evenly
distributed between treatment groups. This clinical trial was conducted across
nineteen sites in the USA and enrolled 171 patients with positive fungal
cultures in their vaginal fluid at baseline. Detailed data will be presented at
a future meeting. 


"We are disappointed that the study did not demonstrate efficacy of MGCD290 in
patients with VVC. We will review the data internally and with key opinion
leaders to determine the next steps for the MGCD290 program." said Dr. Charles
Baum, President and Chief Executive Officer of MethylGene. "The company's
primary focus will continue to be the advancement of our novel oncology
compounds. We expect to provide further updates on the oncology programs in the
second half of 2013." 


About MGCD290

MGCD290 is a first-in-class, orally available, small molecule inhibitor of the
fungal enzyme Hos2. In preclinical models the combination with azole antifungal
agents results in broader coverage of fungal pathogens and decreases resistance
to the most widely used antifungal agents. MGCD290 was being developed as a
combination product with fluconazole, the most widely used triazole antifungal.
In vitro, MGCD290 in combination with fluconazole reverses fluconazole
resistance (primary and acquired) in a wide range of fungal species, including
Candida glabrata. MGCD290 has completed multiple Phase I studies in healthy
adult volunteers and has shown an excellent safety profile without drug-drug
interactions in combination with fluconazole. 


About MethylGene

MethylGene Inc. (TSX:MYG) is a drug development company that is advancing novel
therapeutics for the treatment of patients with cancer and infectious disease in
human clinical trials. The Company's lead product candidates are: MGCD290, an
oral antifungal agent targeting the fungal Hos2 enzyme that was in Phase II
trials for vulvovaginal candidiasis, and MGCD265, a multi-targeted receptor
tyrosine kinase inhibitor that is in Phase I/II clinical trials for patients
with solid tumors. MethylGene owns all rights to its lead product candidates,
and has partnerships with Otsuka Pharmaceutical Co. Ltd., Taiho Pharmaceutical
Co. Ltd., and EnVivo Pharmaceuticals, Inc. for its other pipeline programs.


Certain statements contained in this news release, other than statements of fact
that are independently verifiable at the date hereof, may constitute
forward-looking information and forward-looking statements (collectively
"forward-looking statements" within the meaning of applicable securities laws).
Such statements, based as they are on the current expectations of management of
MethylGene and upon what management believes to be reasonable assumptions,
inherently involve numerous risks and uncertainties, known and unknown, many of
which are beyond MethylGene's control. Such statements can usually be identified
by the use of words such as "may", "would", "believe", "plan", "estimate" and
other similar terminology, or state that certain actions, events or results
"may" or "would" be taken, occur or be achieved These risks and uncertainties
could cause future results, performance or achievements to differ significantly
from the results, performance or achievements expressed or implied by such
forward-looking statements. Such results, performance or achievements include,
but are not limited to, the timing and effects of regulatory action; the
continuation of collaborations; the results of clinical trials; the timing of
enrollment or completion of clinical trials; the success, efficacy or safety of
MGCD265, MGCD290 or our other programs; the ability to scale up, formulate and
manufacture sufficient GMP, clinical or commercialization quantities of MGCD265,
MGCD290 or our other products, and the relative success or the lack of success
in developing and gaining regulatory approval and/or market acceptance for any
compound or new product including MGCD265 or MGCD290.


Such risks include, but are not limited to, the impact of general economic
conditions, economic conditions in the pharmaceutical industry, changes in the
regulatory environment in the jurisdictions in which MethylGene does business,
stock market volatility, fluctuations in costs, expectations with respect to our
intellectual property position and our ability to protect our intellectual
property and operate our business without infringing upon the intellectual
property rights of others, changes in the competitive landscape including
changes in the standard of care for the various indications in which MethylGene
is involved, and changes to the competitive environment due to consolidation, as
well as other risks, as described in MethylGene's Annual Information Form under
the heading "Risk Factors" which you are urged to read, and all other documents
filed by the Company that can be found at www.sedar.com. Consequently, actual
future results may differ materially from the anticipated results expressed in
the forward-looking statements. The reader should not place undue reliance on
the forward-looking statements included in this news release. These statements
speak only as of the date they are made and MethylGene expressly disclaims any
duty, obligation or undertaking to release publicly any updates or revisions to
any forward-looking statements contained herein to reflect any change in
MethylGene's expectations with regard thereto of any change in events,
conditions or circumstances on which any such statements are based except in
accordance with law.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Investor Relations Contact:
MethylGene, Inc.
Mark J. Gergen
Executive Vice President & COO
858-546-2902


MethylGene, Inc.
Tracey Rowlands, Ph.D.
Manager Business and Corporate Development
514-337-3333 ext. 512
ir@methylgene.com
www.methylgene.com


The Trout Group LLC
Thomas Hoffmann
Vice President
646-378-2931
thoffmann@troutgroup.com
www.troutgroup.com

Grafico Azioni VVC Exploration (TSXV:VVC)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni VVC Exploration (TSXV:VVC)
Storico
Da Giu 2023 a Giu 2024